A Phase 4 interventional study of Mexidol sequential therapy in Metabolic Abnormalities, Obesity & Overweight and Cerebral Atherosclerosis, sponsored by Research Center of Neurology, Russia. Active, not recruiting at 1 site in Russia. Open to participants aged 50 Years to 74 Years. Per ClinicalTrials.gov, last updated 2026-11-06.
Sponsored by Research Center of Neurology, Russia · Phase 4, Interventional, and Treatment
We aim to elucidate the metabolic and neuroactive properties of sequential Mexidol therapy in patients with and without cerebrometabolic disorders using blood biomarkers, anthropometry and brain functional MRI (task- and rest).
11,522 studies on the registry are indexed under Obesity; 2,033 are open to participants now.
This study's enrollment of 30 is below the median of 67 across 9,006 interventional studies indexed under Obesity.
Browse Obesity studies →Research Center of Neurology, Russia is the lead sponsor of 5 studies on the registry; 3 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Mexidol sequential therapy
Drug: Mexidol sequential therapy
14 days of 10,0 ml of Mexidol intravenous, followed by 2 months of oral administration
fMRI
Functional brain imaging changes (rest and task-based) - pre- and post-saline vs pre- and post-Mexidol
Time frame: Days 1,2,14,74
BMI
Body mass index canhge
Time frame: 74 days
Cognitive
Cognitive dynamics via MOCA test (maximum - 30, more = better)
Time frame: 74 days
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Research Center of Neurology, Russia